SEC Form 4 · accession 0001104659-26-074045
Sagimet Biosciences Inc. · SGMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Kemble
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 15, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001400118
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.48 | Jun 12, 2026 | A | 39,567 | A | — | Jun 11, 2036 | Series A Common Stock | 39,567 | 39,567 | D |
Explanation of responses
- F1The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.